,address1,address2,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,3980 Premier Drive,Suite 310,High Point,NC,27265,United States,336 841 0300,336 841 0310,https://vtvtherapeutics.com,Biotechnology,Healthcare,"vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593; and license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.",13,"{'maxAge': 1, 'name': 'Dr. Jonathan L. Isaacsohn FACC, M.D.', 'age': 68, 'title': 'Exec. Chairperson', 'yearBorn': 1954, 'fiscalYear': 2022, 'totalPay': 0, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.5,0.48,0.4451,0.52,0.5,0.48,0.4451,0.52,0.0,-1.126901,-1.3487879,106349,106349,174254,38430,38430,0.4603,0.5198,900,1000,36268352,0.424,1.12,4029.817,0.63616,0.764605,0.0,0.0,USD,42950352,0.0,26064974,81483600,1205942,1206404,1690761600,1693440000,0.0148,0.64474,0.04452,3.29,0.0269,-0.31,1672444800,1703980800,1688083200,-19124000,-0.2,-0.33,4772.261,-1.569,NCM,EQUITY,VTVT,VTVT,vTv Therapeutics Inc.,vTv Therapeutics Inc.,1438263000,America/New_York,EDT,-14400000,0.4451,2.0,2.0,2.0,2.0,2.0,buy,1,12614000,0.155,-27367000,417000,1.358,1.501,9000,0.0,-0.5777,-49.78296,-9933000,-4872875,-27040000,0.0,0.0,-3051.0,USD,
1,3980 Premier Drive,Suite 310,High Point,NC,27265,United States,336 841 0300,336 841 0310,https://vtvtherapeutics.com,Biotechnology,Healthcare,"vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593; and license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.",13,"{'maxAge': 1, 'name': 'Mr. Paul J. Sekhri M.Sc., MSc', 'age': 64, 'title': 'CEO, Pres & Director', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 483431, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.5,0.48,0.4451,0.52,0.5,0.48,0.4451,0.52,0.0,-1.126901,-1.3487879,106349,106349,174254,38430,38430,0.4603,0.5198,900,1000,36268352,0.424,1.12,4029.817,0.63616,0.764605,0.0,0.0,USD,42950352,0.0,26064974,81483600,1205942,1206404,1690761600,1693440000,0.0148,0.64474,0.04452,3.29,0.0269,-0.31,1672444800,1703980800,1688083200,-19124000,-0.2,-0.33,4772.261,-1.569,NCM,EQUITY,VTVT,VTVT,vTv Therapeutics Inc.,vTv Therapeutics Inc.,1438263000,America/New_York,EDT,-14400000,0.4451,2.0,2.0,2.0,2.0,2.0,buy,1,12614000,0.155,-27367000,417000,1.358,1.501,9000,0.0,-0.5777,-49.78296,-9933000,-4872875,-27040000,0.0,0.0,-3051.0,USD,
2,3980 Premier Drive,Suite 310,High Point,NC,27265,United States,336 841 0300,336 841 0310,https://vtvtherapeutics.com,Biotechnology,Healthcare,"vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593; and license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.",13,"{'maxAge': 1, 'name': 'Mr. Steven  Tuch M.B.A.', 'age': 53, 'title': 'Exec. VP & CFO', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 449159, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.5,0.48,0.4451,0.52,0.5,0.48,0.4451,0.52,0.0,-1.126901,-1.3487879,106349,106349,174254,38430,38430,0.4603,0.5198,900,1000,36268352,0.424,1.12,4029.817,0.63616,0.764605,0.0,0.0,USD,42950352,0.0,26064974,81483600,1205942,1206404,1690761600,1693440000,0.0148,0.64474,0.04452,3.29,0.0269,-0.31,1672444800,1703980800,1688083200,-19124000,-0.2,-0.33,4772.261,-1.569,NCM,EQUITY,VTVT,VTVT,vTv Therapeutics Inc.,vTv Therapeutics Inc.,1438263000,America/New_York,EDT,-14400000,0.4451,2.0,2.0,2.0,2.0,2.0,buy,1,12614000,0.155,-27367000,417000,1.358,1.501,9000,0.0,-0.5777,-49.78296,-9933000,-4872875,-27040000,0.0,0.0,-3051.0,USD,
3,3980 Premier Drive,Suite 310,High Point,NC,27265,United States,336 841 0300,336 841 0310,https://vtvtherapeutics.com,Biotechnology,Healthcare,"vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593; and license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.",13,"{'maxAge': 1, 'name': 'Mr. Barry  Brown', 'age': 61, 'title': 'Chief Accounting Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 311977, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.5,0.48,0.4451,0.52,0.5,0.48,0.4451,0.52,0.0,-1.126901,-1.3487879,106349,106349,174254,38430,38430,0.4603,0.5198,900,1000,36268352,0.424,1.12,4029.817,0.63616,0.764605,0.0,0.0,USD,42950352,0.0,26064974,81483600,1205942,1206404,1690761600,1693440000,0.0148,0.64474,0.04452,3.29,0.0269,-0.31,1672444800,1703980800,1688083200,-19124000,-0.2,-0.33,4772.261,-1.569,NCM,EQUITY,VTVT,VTVT,vTv Therapeutics Inc.,vTv Therapeutics Inc.,1438263000,America/New_York,EDT,-14400000,0.4451,2.0,2.0,2.0,2.0,2.0,buy,1,12614000,0.155,-27367000,417000,1.358,1.501,9000,0.0,-0.5777,-49.78296,-9933000,-4872875,-27040000,0.0,0.0,-3051.0,USD,
4,3980 Premier Drive,Suite 310,High Point,NC,27265,United States,336 841 0300,336 841 0310,https://vtvtherapeutics.com,Biotechnology,Healthcare,"vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593; and license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.",13,"{'maxAge': 1, 'name': 'Mr. Richard S. Nelson', 'age': 52, 'title': 'Exec. VP of Corp. Devel. & Director', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 201081, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.5,0.48,0.4451,0.52,0.5,0.48,0.4451,0.52,0.0,-1.126901,-1.3487879,106349,106349,174254,38430,38430,0.4603,0.5198,900,1000,36268352,0.424,1.12,4029.817,0.63616,0.764605,0.0,0.0,USD,42950352,0.0,26064974,81483600,1205942,1206404,1690761600,1693440000,0.0148,0.64474,0.04452,3.29,0.0269,-0.31,1672444800,1703980800,1688083200,-19124000,-0.2,-0.33,4772.261,-1.569,NCM,EQUITY,VTVT,VTVT,vTv Therapeutics Inc.,vTv Therapeutics Inc.,1438263000,America/New_York,EDT,-14400000,0.4451,2.0,2.0,2.0,2.0,2.0,buy,1,12614000,0.155,-27367000,417000,1.358,1.501,9000,0.0,-0.5777,-49.78296,-9933000,-4872875,-27040000,0.0,0.0,-3051.0,USD,
5,3980 Premier Drive,Suite 310,High Point,NC,27265,United States,336 841 0300,336 841 0310,https://vtvtherapeutics.com,Biotechnology,Healthcare,"vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593; and license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.",13,"{'maxAge': 1, 'name': 'Dr. Carmen  Valcarce Ph.D.', 'title': 'Chief Scientific Officer & Exec. VP', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.5,0.48,0.4451,0.52,0.5,0.48,0.4451,0.52,0.0,-1.126901,-1.3487879,106349,106349,174254,38430,38430,0.4603,0.5198,900,1000,36268352,0.424,1.12,4029.817,0.63616,0.764605,0.0,0.0,USD,42950352,0.0,26064974,81483600,1205942,1206404,1690761600,1693440000,0.0148,0.64474,0.04452,3.29,0.0269,-0.31,1672444800,1703980800,1688083200,-19124000,-0.2,-0.33,4772.261,-1.569,NCM,EQUITY,VTVT,VTVT,vTv Therapeutics Inc.,vTv Therapeutics Inc.,1438263000,America/New_York,EDT,-14400000,0.4451,2.0,2.0,2.0,2.0,2.0,buy,1,12614000,0.155,-27367000,417000,1.358,1.501,9000,0.0,-0.5777,-49.78296,-9933000,-4872875,-27040000,0.0,0.0,-3051.0,USD,
6,3980 Premier Drive,Suite 310,High Point,NC,27265,United States,336 841 0300,336 841 0310,https://vtvtherapeutics.com,Biotechnology,Healthcare,"vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593; and license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.",13,"{'maxAge': 1, 'name': 'Vanessa  McDade', 'title': 'Chief Admin. Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.5,0.48,0.4451,0.52,0.5,0.48,0.4451,0.52,0.0,-1.126901,-1.3487879,106349,106349,174254,38430,38430,0.4603,0.5198,900,1000,36268352,0.424,1.12,4029.817,0.63616,0.764605,0.0,0.0,USD,42950352,0.0,26064974,81483600,1205942,1206404,1690761600,1693440000,0.0148,0.64474,0.04452,3.29,0.0269,-0.31,1672444800,1703980800,1688083200,-19124000,-0.2,-0.33,4772.261,-1.569,NCM,EQUITY,VTVT,VTVT,vTv Therapeutics Inc.,vTv Therapeutics Inc.,1438263000,America/New_York,EDT,-14400000,0.4451,2.0,2.0,2.0,2.0,2.0,buy,1,12614000,0.155,-27367000,417000,1.358,1.501,9000,0.0,-0.5777,-49.78296,-9933000,-4872875,-27040000,0.0,0.0,-3051.0,USD,
7,3980 Premier Drive,Suite 310,High Point,NC,27265,United States,336 841 0300,336 841 0310,https://vtvtherapeutics.com,Biotechnology,Healthcare,"vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593; and license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.",13,"{'maxAge': 1, 'name': 'Ms. Elizabeth M. Keiley', 'age': 56, 'title': 'Exec. VP & Gen. Counsel', 'yearBorn': 1966, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.5,0.48,0.4451,0.52,0.5,0.48,0.4451,0.52,0.0,-1.126901,-1.3487879,106349,106349,174254,38430,38430,0.4603,0.5198,900,1000,36268352,0.424,1.12,4029.817,0.63616,0.764605,0.0,0.0,USD,42950352,0.0,26064974,81483600,1205942,1206404,1690761600,1693440000,0.0148,0.64474,0.04452,3.29,0.0269,-0.31,1672444800,1703980800,1688083200,-19124000,-0.2,-0.33,4772.261,-1.569,NCM,EQUITY,VTVT,VTVT,vTv Therapeutics Inc.,vTv Therapeutics Inc.,1438263000,America/New_York,EDT,-14400000,0.4451,2.0,2.0,2.0,2.0,2.0,buy,1,12614000,0.155,-27367000,417000,1.358,1.501,9000,0.0,-0.5777,-49.78296,-9933000,-4872875,-27040000,0.0,0.0,-3051.0,USD,
